The primary endpoint was the change from baseline in the 17-item Hamilton Rating Scale for Depression HAMD-17 total score at Day 15.
About the SKYLARK Study The SKYLARK Study 217-PPD-301 was a Phase 3, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of zuranolone 50 mg compared to placebo in adult women with severe PPD.
Click on Icon to view the image gallery.
Sage Therapeutics to host conference call today at 8:00 am ET CAMBRIDGE, Mass.